Hematología y Hemoterapia

Resultados: 414
Tipo Título / Nombre Autor(es) Año
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, Vives S, Bergua JM, Torrent A, et al 2021
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C..., Bergua JM, et al 2021
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Álvarez RM..., Bermejo N, et al 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, et al 2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q..., Bergua JM, et al 2021
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, et al 2021
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M..., Bañas MH, et al. 2021
A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect Palma-Barqueros V, Crescente M, de la Morena ME, Chan MV, Almarza E, Revilla N, et al 2021
Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J..., Bergua Burgues JM, et al 2021
Evolving treatment patterns and outcomes in older patients (?60 years) with AML: changing everything to change nothing? Martínez-Cuadrón D, Serrano J, Gil C, Tormo M, Martínez-Sánchez P..., Bergua J, et al 2021